Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Globe Newswire•06/08/2026•16:01 ET
0
Whiz Insights
* Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue
* Advanced TransportVehicle™ portfolio with two Alzheimer’s disease programs now in clinical development
Get started
Create a free account to read the full story.